The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study
NCT ID: NCT05560373
Last Updated: 2022-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2022-09-30
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage
NCT04509323
Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study
NCT00841633
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
NCT02367248
Searching a Dysfunction of Corticotropic & Thyrotropin Axis During the Acute Phase of a Subarachnoid Hemorrhage Secondary to Spontaneous Rupture of Cerebral Aneurysm
NCT03655509
Drug Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage
NCT04940273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The operation group-The treatment group
after operational treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
Huperzine A injection, operational treatment, the best basic treatment
intramuscular
The operation group-The control group
after operational treatment: ①the best basic treatment
operational treatment, the best basic treatment
other
The intervention group-The treatment group
after interventional treatment: ①the best basic treatment ②i.m. huperzine A injection (0.2mg), qd, 8d.
Huperzine A injection, interventional treatment, the best basic treatment
intramuscular
The intervention group-The control group
after interventional treatment: ①the best basic treatment
Interventional treatment, the best basic treatment
other
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Huperzine A injection, operational treatment, the best basic treatment
intramuscular
operational treatment, the best basic treatment
other
Huperzine A injection, interventional treatment, the best basic treatment
intramuscular
Interventional treatment, the best basic treatment
other
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients were proved to be aneurysmal subarachnoid hemorrhage by imaging examination (head CT, CT angiography (CTA), whole brain angiography (DSA));
* Hunt Hess was graded I-III at admission;
* The patients were treated with endovascular therapy or craniotomy and clipping surgery;
* The time from the onset of aSAH symptoms to admission ≤ 72 hours; ⑥ The subject himself or the guardian of the subject knew and voluntarily signed the informed consent form.
Exclusion Criteria
* Cognitive dysfunction existed before onset;
* Patients with angina pectoris, bronchial asthma, mechanical intestinal obstruction, liver and kidney insufficiency, and urinary tract obstruction;
* Complicated with other nervous system diseases, including nervous system degenerative diseases (Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, etc.), neuromyelitis optica, epilepsy, central nervous system infection (such as AIDS, syphilis, etc.), brain traumatic dementia, etc;
* Psychotic patients, according to DSM-IV-TR standards, including schizophrenia or other mental diseases, bipolar disorder, major depression or delirium;
* Other cholinesterase inhibitor drugs are being used; ⑦ There are uncorrectable visual and auditory disorders, and neuropsychological tests and scales cannot be completed;
* Have unstable or serious heart, lung, liver, kidney and hematopoietic system diseases;
* Pregnant or lactating women and women of childbearing age without reliable contraception, and there is no evidence of negative pregnancy; ⑩ Patients who cannot be followed up as required during the study period; ⑪ Those who are allergic to the test drug; ⑫ Those who have participated in other clinical trials in recent 3 months; ⑬ Patients who are not suitable to participate in the clinical trial.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Wanbangde Pharmaceutical Group Co., LTD
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chen Jingsen
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20220784
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.